Amgen Inc. (AMGN) SEC Filings & Earnings Calls

TAVNEOS withdrawal risk

“On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS.” · word for word

IRS transfer pricing dispute

“The Notices seek to increase our U.S. taxable income for the years 2010–2012 by an amount that would result in additional federal tax of approximately $3.6 billion, plus interest.” · word for word

IRA drug pricing impact

“In January 2025, as part of the IRA, the Company’s product Otezla was selected by CMS for Medicare price setting that will be applicable beginning on January 1, 2027.” · word for word

High debt level

“Total debt carrying value $57,304 million as of June 30, 2026.”

Prolia and XGEVA facing biosimilar competition with volume and price declines

“Prolia sales decreased 32% year-over-year... driven by 20% lower volume and 12% lower net selling price as multiple biosimilars have launched globally with more biosimilars expected. XGEVA sales decreased 34% year-over-year... driven by 22% lower volume and 8% lower net selling price as multiple biosimilars have launched globally with more biosimilars expect”

Enbrel impacted by Medicare Part D price setting under Inflation Reduction Act

“Enbrel sales decreased 4% year-over-year... The decline in net selling price reflects the impact of U.S. Medicare Part D price setting under the Inflation Reduction Act, effective January 1, 2026, as well as an increased 340B Program mix.”

Data exfiltration of proprietary and patient data from third-party cloud environments; potential regulatory, legal, and reputational risks.

“some of its data, including proprietary data, patient protected health information, and other information, has been exfiltrated from these cloud environments.” · word for word

CFO transition risk; new CFO based in Switzerland initially, relocation to US; compensation includes retention bonuses.

“Mr. Dittrich will initially be based in Rotkreuz, Switzerland... expected to relocate to Thousand Oaks, California in connection with his transition to Chief Financial Officer in September 2026.” · word for word

TAVNEOS withdrawal risk

“On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS” · word for word

IRA Medicare price setting adverse impact

“The IRA’s Medicare price setting and Medicare redesign have had, and are likely to have, an adverse effect on our sales, our business and our results of operations” · word for word

State PDAB pricing pressure on ENBREL

“Colorado PDAB established an Upper Payment Limit (UPL) substantially lower than the wholesale acquisition cost of ENBREL” · word for word

340B program expansion negative impact

“inappropriate expanded utilization of the 340B Program from broadened application of the 340B discounts has had, and is expected to continue to have, a negative impact on the Company’s product sales” · word for word

Payer consolidation pricing pressure

“significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations” · word for word

Prolia sales declining due to biosimilar competition; Enbrel impacted by Medicare Part D price setting.

“Prolia sales decreased 34% year-over-year; Enbrel sales decreased 37% year-over-year.”

Pipeline Execution Risk

“The enterprise-level risks are overseen by the Board and the appropriate Board committee... product development, safety and surveillance” · word for word

Pricing and Access Risk

“value (which includes pricing) and access” · word for word

Regulatory Compliance Risk

“regulatory risks associated with the requirements of U.S. federal health care programs, the U.S. Food and Drug Administration, or FDA, and other regulatory agencies” · word for word

Increased leverage with $4B in new debt; interest expense will increase.

“Issued $4B in senior notes with interest rates ranging from 4.200% to 5.650%.”

Cybersecurity Breach Risk

“A breakdown of our information technology systems, cyberattack or information security breach could significantly compromise the confidentiality, integrity and availability of our information technology systems...and/or affect our reputation.” · word for word

Acquisition Integration Risk

“Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.” · word for word

Tariff Cost Risk

“recent increases in tariffs imposed on certain goods imported into the United States, including inputs relevant to biopharmaceutical manufacturing, have raised our production costs to a limited degree in 2025” · word for word

IRA drug pricing pressure leading to impairment charges and margin impact

“Otezla intangible asset impairment charges of $1.2 billion recorded in 2025, following the selection of Otezla for Medicare price setting, as part of the Inflation Reduction Act (IRA)” · word for word

Biosimilar competition for Prolia expected to accelerate sales erosion in 2026

“For 2026, we expect accelerated sales erosion driven by increased competition, as multiple biosimilars have launched globally.” · word for word

Generic competition for RAVICTI in ultra-rare segment

“For 2026, we expect continued RAVICTI sales erosion driven by generic competition.” · word for word

Net selling price declines across key products (Repatha, Prolia, Enbrel)

“For 2026, we expect net selling price to decline by roughly mid single-digits for Repatha; Enbrel sales decreased 48% year-over-year, primarily driven by 35% lower net selling price” · word for word

Loss of collaboration revenue and potential pipeline impact from terminated license agreement.

“Termination of License and Collaboration Agreement with Kyowa Kirin, effective upon regulatory approval.”

IRA Medicare Price Setting and Redesign

“The IRA’s Medicare price setting and Medicare redesign are likely to have a material adverse effect on our sales, our business and our results of operations, and such impact is expected to increase through the end of the decade” · word for word

State PDAB and 340B Expansion

“The Colorado PDAB deemed three of five drugs 'unaffordable,' including ENBREL, and in October 2025 the Colorado PDAB established an Upper Payment Limit (UPL) substantially lower than the wholesale acquisition cost of ENBREL” · word for word

Biosimilar Competition

“Amgen and Biocon have reached a confidential settlement that allowed Biocon to launch its biosimilar products in the United States as early as October 1, 2025.” · word for word

Commercial Payer Pricing Pressure

“We reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha” · word for word

Biosimilar competition for Prolia and XGEVA expected to cause sales erosion.

“For the remainder of 2025, we expect sales erosion driven by biosimilar competition, as biosimilars have launched in the U.S. market.” · word for word

Otezla intangible asset impairment of $400M indicates potential overpayment or reduced future cash flows.

“Otezla intangible asset impairment charge of $400 million recorded during Q3 2025.” · word for word

Enbrel sales declined 30% due to Medicare Part D redesign and 340B mix, impacting net selling price.

“Enbrel sales decreased 30% year-over-year to $580 million, driven by 38% lower net selling price resulting from Medicare Part D redesign and increased 340B Program mix.”